Last week, our phase 1b trial WHV138 has reached a new milestone: The first enrolled volunteer has completed the trial with their final study visit, two years after trial enrollment.
This Group 1 participant has received four vaccinations with the heterologous HIV vaccine candidate PDPHV over the course of 12 months, followed by a 12-month safety observation period. All trial volunteers are expected to complete the trial within the next several months, with the very final visit in Group 2 to be expected by December of this year.
WHV is grateful for all volunteers’ commitment in participating in this early research phase of PDPHV. Without them, advancement in HIV vaccine science would not be possible. PDPHV is currently the only HIV Vaccine candidate tested in humans using a 5-plasmid DNA vaccine combined with matched antigens in the quadrivalent Protein vaccine component. If proven to be efficacious, PDPHV may be a promising vaccine candidate in the utilization as an HIV prevention method worldwide. Preparations to advance PDPHV into a phase 2 research study are ongoing.
